Epoprostenol in Pulmonary Embolism

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

You are admitted to hospital because of pulmonary embolism. You are treated with anticoagulants.

The investigators know that, despite this treatment, pulmonary embolism can be a threat especially if heart function is compromized.

The investigators investigate a well known study drug (epoprostenol) on top of regular treatment with anticoagulants, to see if heart function can be optimized

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Free University Medical Center
• Treatments: Epoprostenol; Tezosentan

Criteria

Inclusion Criteria:

• acute (symptoms <24 hrs) with right ventricular dilatation (>30 mm end diastolic, systolic PAP > 50 mmHg,

• absence of right ventricular wall hypertrophy)

Exclusion Criteria:

• age below 18 years or above 70 years

• body mass index >35 kg/m2

• duration of symptoms >24 hours (since onset or acute increase in symptoms)

• severe circulatory shock (systemic blood pressure systolic <80 mmHg, or diastolic blood pressure <45 mmHg) or respiratory failure, requiring mechanical ventilation.

• patients who, in the opinion of the supervising physician, require thrombolytic therapy.

• severe pre-existent cardiopulmonary disease (heart failure, obstructive pulmonary disease, emphysema)

• atrial fibrillation

• refusal or inability to give informed consent